Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent typhoid and paratyphoid A conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bivalent typhoid and paratyphoid A conjugate vaccine is an investigational vaccine being developed by Zydus Lifesciences to provide protection against enteric fever caused by *Salmonella Typhi* and *Salmonella Paratyphi A*. As a conjugate vaccine, it works by linking bacterial polysaccharides to a carrier protein to enhance the immune response, particularly in young children. This bivalent approach represents a significant advancement over existing monovalent typhoid vaccines, as paratyphoid A accounts for a substantial proportion of enteric fever cases in endemic regions like Asia. The vaccine is currently in Phase 1/2 clinical development, with studies designed to evaluate its safety and immunogenicity compared to established monovalent typhoid conjugate vaccines.
- Other names
- bivalent typhoid and paratyphoid A conjugate vaccineTyphoid-Paratyphoid A conjugate vaccine
02
Targets
Paratyphi A antigen (Salmonella Paratyphi A antigen)Vi antigen (Vi capsular polysaccharide)
Beyond the preview
Go deeper on bivalent typhoid and paratyphoid A conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent typhoid and paratyphoid A conjugate vaccine.